Nevertheless, current therapies such as renin-angiotensin-aldosterone system or sodium-glucose cotransporter 2 inhibitors cannot impede the malignancy of DKD, partly due to the incomplete understanding of the complicated etiology. Here, SLC5A2 is linked to diabetic kidney disease.